Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19381847 | 0.85 | BTK (0.50) | BTKCA1CA2GAAEPHX1 | |
| SCHEMBL14669045 | 0.85 | BTK (0.49) | BTKCA1CA2GAAEPHX1 | |
| SCHEMBL21549474 | 0.84 | BTK (0.54) | BTKCA1CA2GAAEPHX1 | |
| SCHEMBL18928233 | 0.83 | BTK (0.52) | BTKCA1CA2GAAEPHX1 | |
| SCHEMBL13961431 | 0.83 | BTK (0.52) | BTKCA1CA2GAAEPHX1 | |
| SCHEMBL29180734 | 0.83 | BTK (0.52) | BTKCA1CA2GAAEPHX1 | |
| SCHEMBL15542360 | 0.83 | BTK (0.52) | BTKCA1CA2GAAEPHX1 | |
| SCHEMBL18925569 | 0.83 | BTK (0.52) | BTKCA1CA2GAAEPHX1 | |
| SCHEMBL31402079 | 0.81 | BTK (0.50) | BTKCA1CA2GAAEPHX1 | |
| SCHEMBL31645007 | 0.81 | BTK (0.54) | BTKCA1CA2GAAEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2867227-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2018-11-21 | — | — | EP | disclosed |
| US-9487483-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2016-11-08 | — | — | US | disclosed |
| US-9487483-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2016-11-08 | — | — | US | disclosed |
| US-20150148349-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-28 | — | — | US | disclosed |
| US-20150148349-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-28 | — | — | US | disclosed |
| EP-2867227-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | Novartis AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014002058-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148349-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | C5, C3AR1, C9 | BTK 231/4885CA1 4687/4885CA2 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.